- Home
- GOSS vs EOD Comparison
GOSS vs EOD Comparison
Compare GOSS & EOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- EOD
- Stock Information
- Founded
- GOSS 2015
- EOD 2007
- Country
- GOSS United States
- EOD United States
- Employees
- GOSS N/A
- EOD N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- EOD Investment Managers
- Sector
- GOSS Health Care
- EOD Finance
- Exchange
- GOSS Nasdaq
- EOD Nasdaq
- Market Cap
- GOSS 212.9M
- EOD 197.7M
- IPO Year
- GOSS 2019
- EOD N/A
- Fundamental
- Price
- GOSS $0.74
- EOD $4.86
- Analyst Decision
- GOSS Strong Buy
- EOD
- Analyst Count
- GOSS 5
- EOD 0
- Target Price
- GOSS $9.20
- EOD N/A
- AVG Volume (30 Days)
- GOSS 881.6K
- EOD 118.1K
- Earning Date
- GOSS 11-07-2024
- EOD 01-01-0001
- Dividend Yield
- GOSS N/A
- EOD 9.28%
- EPS Growth
- GOSS N/A
- EOD N/A
- EPS
- GOSS N/A
- EOD N/A
- Revenue
- GOSS $105,322,000.00
- EOD N/A
- Revenue This Year
- GOSS N/A
- EOD N/A
- Revenue Next Year
- GOSS N/A
- EOD N/A
- P/E Ratio
- GOSS N/A
- EOD N/A
- Revenue Growth
- GOSS N/A
- EOD N/A
- 52 Week Low
- GOSS $0.50
- EOD $3.73
- 52 Week High
- GOSS $1.60
- EOD $4.71
- Technical
- Relative Strength Index (RSI)
- GOSS 22.63
- EOD 43.62
- Support Level
- GOSS $0.78
- EOD $4.80
- Resistance Level
- GOSS $0.92
- EOD $5.00
- Average True Range (ATR)
- GOSS 0.05
- EOD 0.06
- MACD
- GOSS -0.01
- EOD 0.00
- Stochastic Oscillator
- GOSS 0.00
- EOD 30.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.